Famitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Nasopharyngeal Carcinoma

Conditions

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma

Trial Timeline

Jul 1, 2011 → Aug 1, 2016

NCT ID

NCT01392235

About Famitinib

Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01392235. Target conditions include Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05473468	Phase 1	UNKNOWN	Aug 26, 2022	Nov 1, 2022	Healthy Subjects
NCT04479904	Phase 2	Withdrawn	Aug 10, 2020	Feb 10, 2022	Intrahepatic Cholangiocarcinoma
NCT01762293	Phase 2	Completed	Apr 1, 2012	Oct 1, 2014	Colorectal Cancer
NCT02336724	Phase 2	UNKNOWN	Mar 1, 2012	Jun 1, 2019	Gastrointestinal Stromal Tumor
NCT01994213	Phase 2	Terminated	Oct 1, 2011	May 1, 2016	Gastroenteropancreatic Neuroendocrine Tumor
NCT01392235	Phase 2	Completed	Jul 1, 2011	Aug 1, 2016	Recurrent Nasopharyngeal Carcinoma

Competing Products

20 competing products in Recurrent Nasopharyngeal Carcinoma

See all competitors

Product	Company	Stage	Hype Score
KPL-914	Kiniksa Pharmaceuticals	Phase 2	47
KPL-387	Kiniksa Pharmaceuticals	Phase 2	47
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	72
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	33
Zopapogene imadenovec (Zopa)	Precigen	Approved	80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	36
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	52
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	41
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	33
PLX3397	Daiichi Sankyo	Phase 2	52
erlotinib + etoposide	Astellas Pharma	Phase 2	52
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	52
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Eribulin Mesylate	Eisai	Pre-clinical	23
Lenvatinib + Everolimus	Eisai	Phase 1/2	41
E7090	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved